Logo image of SABS

SAB BIOTHERAPEUTICS INC (SABS) Stock Fundamental Analysis

NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock - Currency: USD

1.82  -0.13 (-6.67%)

After market: 1.76 -0.06 (-3.3%)

Fundamental Rating

1

SABS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. SABS may be in some trouble as it scores bad on both profitability and health. SABS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SABS has reported negative net income.
In the past year SABS has reported a negative cash flow from operations.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 20M -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -84.70%, SABS is doing worse than 70.52% of the companies in the same industry.
SABS's Return On Equity of -123.48% is on the low side compared to the rest of the industry. SABS is outperformed by 60.21% of its industry peers.
Industry RankSector Rank
ROA -84.7%
ROE -123.48%
ROIC N/A
ROA(3y)-36.07%
ROA(5y)N/A
ROE(3y)-59.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 20 -20 40 -40 -60

1.3 Margins

SABS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SABS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for SABS has been reduced compared to a year ago.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2M 4M 6M 8M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -4.95, we must say that SABS is in the distress zone and has some risk of bankruptcy.
SABS's Altman-Z score of -4.95 is on the low side compared to the rest of the industry. SABS is outperformed by 61.28% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that SABS is not too dependend on debt financing.
SABS has a worse Debt to Equity ratio (0.09) than 66.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -4.95
ROIC/WACCN/A
WACC9.11%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

SABS has a Current Ratio of 3.69. This indicates that SABS is financially healthy and has no problem in meeting its short term obligations.
SABS's Current ratio of 3.69 is in line compared to the rest of the industry. SABS outperforms 43.34% of its industry peers.
SABS has a Quick Ratio of 3.69. This indicates that SABS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.69, SABS is in line with its industry, outperforming 44.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 3.69
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SABS have decreased strongly by -43.66% in the last year.
The Revenue for SABS has decreased by -63.05% in the past year. This is quite bad
The Revenue for SABS have been decreasing by -65.65% on average. This is quite bad
EPS 1Y (TTM)-43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12%
Revenue 1Y (TTM)-63.05%
Revenue growth 3Y-65.65%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

SABS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.66% yearly.
Based on estimates for the next years, SABS will show a decrease in Revenue. The Revenue will decrease by -5.35% on average per year.
EPS Next Y48.44%
EPS Next 2Y25.74%
EPS Next 3Y17.66%
EPS Next 5YN/A
Revenue Next Year0.6%
Revenue Next 2Y-12.85%
Revenue Next 3Y-1.72%
Revenue Next 5Y-5.35%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as SABS's earnings are expected to grow with 17.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.74%
EPS Next 3Y17.66%

More info and screens

0

5. Dividend

5.1 Amount

SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (2/21/2025, 8:00:01 PM)

After market: 1.76 -0.06 (-3.3%)

1.82

-0.13 (-6.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners28.14%
Inst Owner Change-99.38%
Ins Owners18.43%
Ins Owner Change0%
Market Cap16.80M
Analysts84
Price Target12.65 (595.05%)
Short Float %1.59%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.36%
Min EPS beat(2)-0.74%
Max EPS beat(2)31.46%
EPS beat(4)2
Avg EPS beat(4)-91.26%
Min EPS beat(4)-434.47%
Max EPS beat(4)38.73%
EPS beat(8)5
Avg EPS beat(8)-47.94%
EPS beat(12)8
Avg EPS beat(12)-60.12%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)-0.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.24%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)-20%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.1
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-5.89
EYN/A
EPS(NY)-3.05
Fwd EYN/A
FCF(TTM)-4.18
FCFYN/A
OCF(TTM)-4.14
OCFYN/A
SpS0.16
BVpS4
TBVpS4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.7%
ROE -123.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.07%
ROA(5y)N/A
ROE(3y)-59.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.19%
Cap/Sales 23.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 3.69
Altman-Z -4.95
F-Score4
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)269.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)11.95%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12%
EPS Next Y48.44%
EPS Next 2Y25.74%
EPS Next 3Y17.66%
EPS Next 5YN/A
Revenue 1Y (TTM)-63.05%
Revenue growth 3Y-65.65%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year0.6%
Revenue Next 2Y-12.85%
Revenue Next 3Y-1.72%
Revenue Next 5Y-5.35%
EBIT growth 1Y-92.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-97.3%
OCF growth 3YN/A
OCF growth 5YN/A